06-Nov-2026 17:09:39

AARTIDRUGS : US FDA ISSUES 3 OBSERVATIONS AT SUBSIDIARY'S BADDI PLANT

• US FDA inspected wholly owned subsidiary Pinnacle Life Science's formulations facility at Baddi, Himachal Pradesh from November 2 to November 6, 2026 • Company received 3 inspectional observations in Form 483; none related to data integrity • Aarti Drugs said there is no impact on financial, operational or other activities from the observations • Company will work closely with US FDA to resolve all points Impact: Neutral (regulatory overhang from unresolved Form 483 observations, but no data-integrity issues or stated financial impact)

Aarti Drugs Limited

← Back to feed